Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 177 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Chemotherapy-induced Peripheral Neuropathy Clear all

Conditions: Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Best Practice, Exercise Counseling, Exercise Intervention, Magnetic Resonance Imaging, Neuropathy Assessment, Questionnaire Administration; Other · Procedure
Lead sponsor: University of Rochester NCORP Research Base; Other
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 93
States / cities: Fresno, California • Martinez, California • Roseville, California + 70 more

Conditions: Pain, Peripheral Neuropathy
Interventions: scrambler therapy, questionnaire administration, management of therapy complications; Other · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breast Cancer, Colon Cancer, Neuropathy
Interventions: topical menthol, placebo lotion; Drug
Lead sponsor: Columbia University; Other
Eligibility: 21 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Gestational Trophoblastic Tumor, Neurotoxicity, Peripheral Neuropathy, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: amifostine trihydrate; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 57
States / cities: Burbank, California • La Jolla, California • Los Angeles, California + 43 more

Conditions: Chemotherapy-induced Peripheral Neuropathy
Interventions: No Intervention, Observational Study; Other
Lead sponsor: Children's National Research Institute; Other
Eligibility: 6 Years to 18 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Breast Carcinoma, Chemotherapy-Induced Peripheral Neuropathy, Colon Carcinoma
Interventions: Biospecimen Collection, Cannabidiol, Dronabinol, Placebo Administration, Survey Administration; Procedure · Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Duarte, California • Irvine, California

Conditions: Neuropathy, Cancer, Chemotherapeutic Drug - Induced Nephropathy, Chemotherapeutic Toxicity
Interventions: Vibration therapy; Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 3
States / cities: Avon, Indiana • Indianapolis, Indiana

Conditions: Chemotherapy-induced Peripheral Neuropathy
Interventions: Nicotinamide riboside, Placebo capsules; Drug
Lead sponsor: Donna Hammond, PhD; Other
Eligibility: 18 Years to 85 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Chemotherapy-Induced Peripheral Neuropathy, Metastatic Breast Carcinoma
Interventions: Paclitaxel, Monosialotetrahexosylganglioside, Questionnaire Administration, Quality-of-life assessment, Placebo Administration; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 33
States / cities: Irvine, California • Orange, California • Clearwater, Florida + 26 more

Conditions: Adenocarcinoma of Pancreas
Interventions: Hand Therapy Until CIPN, Traditional Occupational Therapy (TOT); Other
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients, Metastatic Colorectal Cancer (CRC), Peripheral Neuropathy Due to Chemotherapy
Interventions: Cannabidiol (CBD), oxaliplatin-based chemotherapy; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Peripheral Neuropathy
Interventions: Low Level Laser, Placebo followed by Low Level Laser; Procedure
Lead sponsor: Legacy Health System; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Breast Cancer, Chemotherapy-induced Peripheral Neuropathy, Neuropathic Pain
Interventions: Aerobic exercise, Iyengar yoga; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Palmidrol, Placebo Administration, Quality-of-Life Assessment; Drug · Other
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 10
States / cities: Middletown, Connecticut • Urbana, Illinois • Sioux City, Iowa + 7 more

Conditions: Chemotherapy-induced Peripheral Neuropathy
Interventions: Arm 1: Investigational INF, Arm 2: standardized muscle stretching and strength; Other
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Neuralgia, Neuropathic Pain, Chemotherapy-induced Peripheral Neuropathy
Interventions: Magnetic Peripheral Nerve Stimulation; Device
Lead sponsor: NeuraLace Medical, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Cancer, Breast, Cancer, Colorectal, Cancer, Lung, Cancer, Ovarian
Interventions: aerobic exercise intervention, control group, resistive training; Behavioral · Other
Lead sponsor: Baltimore VA Medical Center; Federal
Eligibility: 21 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Peripheral Neuropathy Due to Chemotherapy
Interventions: Goal Attainment Scaling (GAS); Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chemotherapy-induced Peripheral Neuropathy
Interventions: Video-Guided Acupuncture Imagery Treatment (VGAIT); Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Neuropathy;Peripheral, Chemotherapy-induced Peripheral Neuropathy
Interventions: BXQ-350, Placebo; Drug · Other
Lead sponsor: Bexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Cincinnati, Ohio • Columbus, Ohio • Nashville, Tennessee

Conditions: Chemotherapy Induced Peripheral Neuropathy (CIPN)
Interventions: Ziconotide; Drug
Lead sponsor: Christian Hospital Northeast Northwest; Other
Eligibility: 18 Years to 100 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Peripheral Neuropathic Pain, Neurotoxicity, Cancer
Interventions: Not listed
Lead sponsor: National Institute of Nursing Research (NINR); NIH
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Gynecologic Cancer, Neuropathy;Peripheral
Interventions: SensoniQ Treatment Station; Device
Lead sponsor: Augusta University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Chemotherapy-Induced Peripheral Neuropathy
Interventions: Duloxetine 60 mg qd, Lorcaserin; Drug
Lead sponsor: Southeastern Regional Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Newnan, Georgia

Search by objective public record fields.

Testing the Effects of Exercise on Chemotherapy-Induced Peripheral Neuropathy

Scrambler Therapy in Treating Pain and Peripheral Neuropathy in Patients Previously Treated With Chemotherapy

Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy

Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer

Physiologic Measure of VIPN

Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors

Daily Hand-Held Vibration Therapy

NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy

Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel

Hand Therapy Intervention Versus Traditional Occupational Therapy to Prevent Chemotherapy Induced Peripheral Neuropathy

Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy

Treatment Trial Using Low Level Laser Therapy (LLLT) for Treatment of Chemotherapy Induced Peripheral Neuropathy

Pain, Psychological, and Endocannabinoid Responses to Yoga in Breast Cancer Survivors With Chemotherapy-induced Neuropathic Pain

PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy

Chemotherapy Induced Peripheral Neuropathy (CIPN)

Safety and Effectiveness of Magnetic Peripheral Nerve Stimulation for the Treatment of Chemotherapy Induced Neuropathy

Exercise Effect on Chemotherapy-Induced Neuropathic Pain

Patient-identified Values as Outcome Targets (PIVOT) Feasibility Pilot Trial

VGAIT for Chemotherapy-induced Peripheral Neuropathy

BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients

Intrathecal Ziconotide in Chemotherapy Induced Peripheral Neuropathy

Molecular-Genetic Mechanisms Associated With Chemotherapy-Induced Nerve Damage

The Effect of Low Frequency Soundwave Stimulation on Chemotherapy Induced Peripheral Neuropathy

Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy